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Abstract 
The neurotransmitter serotonin (5-hdroxytryptamine; 5-HT) has been implicated in the 
pathophysiology and treatment of major depression since the serendipitous discovery of 
antidepressant drugs in the 1950s. However, despite the generalised use of serotonin-
enhancing drugs, such as the selective serotonin reuptake inhibitors (SSRIs) and the dual 
serotonin and norepinephrine reuptake inhibitors (SNRIs), the exact neurobiological 
mechanisms involved in the therapeutic action of these drugs are poorly understood. Better 
knowledge of these mechanisms may help to identify new therapeutic targets and to overcome 
the two main limitations of current treatments: reduced efficacy and slowness of action. Here I 
review the preclinical and clinical evidence supporting the involvement of different 5-HT 
receptors in the therapeutic action of antidepressant drugs. Presynaptic 5-HT1A and 5-HT1B 
autoreceptors play a major detrimental role in antidepressant treatments, as their activation by 
the excess of the active (extracellular) 5-HT fraction produced by serotonin transporter (SERT) 
blockade reduces presynaptic serotonergic function. Conversely, stimulation of postsynaptic 5-
HT1A receptors in corticolimbic networks appears beneficial for the antidepressant action. The 5-
HT2 receptor family is also involved as 5-HT2A/2C receptor blockade improves the antidepressant 
action of SSRIs, and recent data suggest that 5-HT2B receptor activation enhances serotonergic 
activity. Less is known from the rest of postsynaptic 5-HT receptors. However, 5-HT3 receptor 
blockade augments the 5-HT increase evoked by SERT inhibition, and 5-HT4 receptor activation 
may have antidepressant effects on its own. Finally, blockade of 5-HT6 and 5-HT7 receptors 
appears also to augment the antidepressant effects of SERT inhibition. 
Keywords: Antidepressant drugs; Major depression; Serotonin transporter; Serotonin receptors; 
SSRI; SNRI 
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DHPC, dorsal hippocampus  
DR, dorsal raphe nucleus 
GABA, γ-aminobutyric acid 
LC; locus coeruleus 
MDD, major depressive disorder 
MnR, median raphe nucleus  
mRNA, messenger ribonucleic acid 
NE, norepinephrine 
NMDA, noncompetitive N-methyl d-aspartate 
PET, positron emission tomography 
PFC, prefrontal cortex  
REM, rapid eye movement 
SERT, serotonin transporter 
SNRI, serotonin and norepinephrine reuptake inhibitors 
SSRI, selective serotonin reuptake inhibitors 
STR, dorsal striatum  
VHPC, ventral hippocampus 
VTA, ventral tegmental area 
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1. Introduction 
Major depressive disorder (MDD) is a severe psychiatric syndrome with high prevalence and 
socioeconomic impact (Andlin-Sobocki et al., 2005; Smith, 2011; Kessler et al., 2005). Although 
it is clear that depression results from, and can result in, changes in the functional 
neuroanatomy of the brain (Sheline et al., 1996; Duman et al., 1997; Drevets et al., 2008; 
Seminowicz et al., 2004), the underlying pathophysiology of MDD has not yet been clearly 
defined. Numerous clinical and preclinical studies indicate that a disturbance in central serotonin 
(5-hydroxytryptamine; 5-HT) activity is a key factor; however, other monoaminergic 
neurotransmitters (e.g. norepinephrine -NE- and dopamine -DA-) have also been implicated 
(Harro and Oreland, 2001; Nestler et al., 2002; Nestler and Carlezon, 2006). More recently, 
glutamatergic neurotransmission has been implicated, based on the observation that ketamine 
(noncompetitive N-methyl d-aspartate -NMDA- receptor antagonist) shows rapid and persistent 
antidepressant effects (Zarate et al., 2006). 
 
Despite the large body of research focusing on the mechanisms underlying antidepressant 
efficacy (Blier and de Montigny, 1994; Artigas et al., 1996; Celada et al., 2004; Berton and 
Nestler, 2006), current antidepressants remain limited – especially in terms of onset of action 
and overall efficacy (Trivedi et al., 2006; Rush et al., 2006; Rush et al, 2011). The aim of this 
article is to review our current knowledge of the role of the serotonergic system in depression, 
including the many serotonergic receptors identified, and how targeting these receptors in novel 
ways may lead to the development of new antidepressants.  
 
2. The serotonin system in depression 
Abnormalities in serotonergic function have been believed to be a common factor in several 
related mental illnesses since the 1950s (Woolley and Shaw, 1954). Since then, the link 
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between serotonin and depression has been further clarified by clinical studies that have shown 
that an acute, transient relapse of depressive symptoms can be produced in subjects in 
remission using the irreversible 5-HT synthesis inhibitor p-chlorophenylalanine (Shopsin et al., 
1975; Shopsin et al., 1976) or tryptophan depletion (Delgado et al., 1990; Price et al., 1990) to 
cause a temporary reduction in central serotonin levels. Overall, these studies show that clinical 
efficacy of antidepressant drugs depends on presynaptic serotonergic function. Similarly, other 
studies have shown reduced cerebrospinal fluid concentrations of the serotonin major 
metabolite – 5-hydroxyindoleacetic acid (5-HIAA) – in drug-free depressed patients (Asberg et 
al., 1976, Roy et al., 1989) as well as reduced concentrations of 5-HT and its main metabolite 
(5-HIAA) in the postmortem brain tissue of depressed and/or suicidal patients.  
 
Perhaps the strongest evidence for the role of the serotonergic system in MDD is the efficacy of 
antidepressants that target the serotonin transporter (SERT) – namely, the selective serotonin 
reuptake inhibitors (SSRIs) and the dual serotonin and norepinephrine reuptake inhibitors 
(SNRIs) – which account for more than 90% of the global antidepressant market. A full review of 
the serotonergic system is beyond the scope of the present article but has been well covered in 
other comprehensive reviews (Azmitia and Whitaker-Azmitia, 1991; Jacobs and Azmitia, 1992; 
Smythies, 2005). However, before focusing on the numerous 5-HT receptors, it is important to 
understand the basic characteristics of the serotonergic system relevant to understanding the 
effects of antidepressant therapy (Box 1).  
 
First, the serotonergic neurons of the mammalian brain comprise the most extensive and 
complex neurochemical network in the central nervous system (CNS) after that of glutamate, 
which makes up the basic wiring of the brain. It has been estimated that the human brain 
contains about 250 000 5-HT neurons of a total of 1011 neurons (Jacobs and Azmitia, 1992). 
Importantly, whereas serotonergic neurons originate mainly in the brainstem dorsal and median 
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raphe nuclei, their axons arborise over large areas such that they innervate almost every area of 
the brain with high densities of axonal varicosities. Hence, densities of >106 nerve 
terminals/mm3 have been reported in rat neocortex (Beaudet and Descarries, 1976).  
 
Second, whereas some serotonergic projections form classical chemical synapses, many do 
not, but instead release 5-HT in a paracrine manner (sometimes termed ’volume transmission’). 
Thirdly, serotonin neurons are tonically active with a slow (~1 Hz) and regular activity that 
ceases during rapid eye movement sleep (REM-off neurons), in parallel with noradrenergic 
neurons of the locus coeruleus (Smythies, 2005). Finally, it is also important to understand that 
under normal conditions, the activity of serotonergic neurons is tightly controlled via a number of 
mechanisms including – among others – glutamatergic inputs from forebrain areas such as the 
prefrontal cortex (Celada et al., 2001; Fink et al., 1995; Martin-Ruiz et al., 2001a), tonic 
noradrenergic input from the pontine nuclei (Peyron et al., 1996; O'Leary et al., 2007; 
VanderMaelen and Aghajanian, 1983), inhibitory γ-aminobutyric acid (GABA)-ergic inputs from 
local interneurons (Bagdy et al., 2000; Gervasoni et al., 2000; Varga et al., 2001) and 
dopaminergic input from the midbrain dopaminergic nuclei (Martin-Ruiz et al., 2001b). In 
addition, the serotonin system is involved in ‘self-regulation’ of serotonergic activity. Indeed, a 
key control mechanism of 5-HT neurons is self-inhibition through 5-HT1A autoreceptors, which 
will be discussed in detail later. Taken together, these basic anatomical and electrophysiological 
characteristics mean that changes in the activity of serotonergic neurons influence a large 
population of target neurons in the forebrain. 
 
Considering the complex nature of the serotonergic system and the interplay with other 
neurochemical systems, numerous mechanisms may play a role in MDD development. 
Currently, mechanisms suggested include low neuronal production of serotonin or of 
postsynaptic receptors, reduced excitatory inputs or excessive self-inhibition, reduced 5-HT 
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synthesis and/or tryptophan shortage. Regardless of the exact mechanisms, depression is 
attributable, at least in part, to abnormal transmission at central 5-HT synapses; therefore, 
agents that modulate serotonergic transmission in the brain are predicted to be effective 
antidepressants.  
 
3. 5-HT receptors  
Following SSRI development, serotonergic targets other than SERT – namely, the 5-HT 
receptors – have received much research attention. Serotonin mediates its wide range of 
physiological functions through interactions with multiple receptors, and to date seven families 
of 5-HT receptors have been identified (5-HT1–5-HT7), some of which have several receptor 
subtypes. Six of the seven subtypes are G-protein–coupled receptors, whereas the 5-HT3 
receptor is a ligand-gated cation channel (reviewed in Hoyer et al., 1994; Barnes and Sharp, 
1999). 
 
3.1. 5-HT1A receptors 
The first major family – the 5-HT1 receptors – is linked to the inhibition of adenylate cyclase and 
mainly function as inhibitory presynaptic and postsynaptic receptors. Of this family, the role of 
the 5-HT1A subtype in depression (more specifically in the mechanism of action of 
antidepressants) is relatively well-established. 5-HT1A receptors are coupled to several 
intracellular signalling mechanism, of which two have received most attention, the negative 
coupling to adenylate cyclase and the opening of K* channels (Barnes and Sharp, 1999; 
Raymond et al., 2001). 5-HT1A receptors are found in two main populations: 1) serotonin 
neurons of the midbrain raphe nuclei (as presynaptic autoreceptors); and 2) postsynaptic 
neurons mainly in the hippocampus, septum, amygdala and corticolimbic areas (Sanabria-
Bohorquez et al., 2002; Pazos and Palacios, 1985; Pompeiano et al., 1992; Martinez et al., 
2001; Santana et al., 2004). As mentioned above, 5-HT1A receptors play an important role in the 
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self-regulation of the serotonergic system. Serotonergic activation of these receptors leads to 
opening of potassium channels in the cell membrane and hyperpolarisation of the cell, which 
results in a reduction in the discharge rate (Sprouse and Aghajanian, 1987; Sprouse and 
Aghajanian, 1986). Given the remarkable role of the neuronal discharge on the overall activity of 
the whole serotonergic system, the reduction in firing rate evoked by 5-HT1A agonists translates 
immediately into a widespread reduction of 5-HT release in most brain areas, yet with a 
preferential effect on dorsal raphe-innervated regions (Hjorth and Sharp, 1991; Adell et al., 
1993; Casanovas and Artigas, 1996; Casanovas et al., 1997).  
 
Activation of 5-HT1A autoreceptors by endogenous 5-HT plays a fundamental role in the 
physiological control of the activity of ascending 5-HT neurons. During waking periods, 5-HT 
neurons show a slow and regular discharge rate (pacemaker activity) (Jacobs and Azmitia, 
1992). Under conditions of excessive excitatory input, such as those produced by stress, an 
increased 5-HT release occurs in the vicinity of cell bodies that activates inhibitory 5-HT1A 
autoreceptors and helps to keep 5-HT neuronal firing low and regular (Adell et al., 1997; Celada 
et al., 2001; Martin-Ruiz and Ugedo, 2001). Thus, 5-HT1A autoreceptors act as physiological 
‘safety valves’ that help to maintain the homeostasis of the system. This physiological negative 
feedback mechanism plays a detrimental role in the mechanism of action of antidepressant 
drugs. Hence, the acute administration of antidepressants (tricyclic drugs, monoamine oxidase  
inhibitors and SSRIs) produces a very large increase of extracellular 5-HT in the midbrain raphe 
(Adell and Artigas, 1991; Bel and Artigas, 1992; Celada and Artigas, 1993), which activates 5-
HT1A receptors and so reduces 5-HT cell firing (Blier and de Montigny, 1994) and terminal 5-HT 
release (Romero et al., 1996; Artigas et al., 1996) (Fig. 1). Importantly, the effectiveness of this 
negative feedback pathway in inhibiting the effects of SSRIs clearly declines with prolonged 
treatment and is likely to result from the serotonin-induced desensitisation of raphe 5-HT1A 
autoreceptors (Blier and de Montigny, 1994; El Mansari et al., 2005; Hervas et al., 2001), which 
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allows extracellular 5-HT to increase markedly more than after single administration (Bel and 
Artigas, 1993; Ferrer and Artigas, 1994; Hervas et al., 2001). It is thought that this feedback 
loop probably explains much of the slow and delayed clinical action of antidepressant drugs 
(Artigas et al., 1996; Artigas et al., 2001).  
 
5-HT1A receptor abnormalities have been reported in patients with MDD. Hence, postmortem 
and neuroimaging studies suggest an increased density of 5-HT1A autoreceptors in major 
depressives compared with control subjects (Stockmeier et al., 1998; Parsey et al., 2006; 
Boldrini et al.,. 2008). Likewise, genetic studies have shown that individuals with elevated 
density or activity of 5-HT1A autoreceptors are more susceptible to mood disorders and respond 
poorly to antidepressants (Lemonde et al., 2003; Neff et al., 2009). However, postsynaptic 5-
HT1A receptors have been shown to be unaltered or reduced in depressed patients, and this 
alteration is not sensitive to antidepressant treatment (Bhagwagar et al., 2004). 
 
In the 1990s, I proposed that “5-HT1A receptor antagonists could accelerate (and perhaps 
augment) the clinical effects of antidepressants by preventing this negative feedback” (Artigas, 
1993) and showed that combining SSRI treatment with the mixed 5-HT1A/β-adrenoceptor 
antagonist pindolol (the only potential 5-HT1A antagonist available for human use by that time) 
markedly reduced the latency of the antidepressant response and increased the clinical 
response in previously untreated patients with MDD (Artigas et al., 1994; Artigas et al., 2006; 
see metanalyses in Whale et al., 2010; Ballesteros and Callado, 2004). However, pindolol 
additon was ineffective in treatment-resistant depressed patients (Perez et al., 1999), and the 
scarcity of 5-HT1A receptor antagonists available for human use has limited the use of the 
’pindolol strategy’ to accelerate/enhance the antidepressant effects of SSRI. Since then, it has 
been of considerable interest to evaluate potential antidepressants that incorporate an action at 
5-HT1A receptors into their mechanism of action. To the best of my knowledge, two new 
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antidepressants [vilazodone, approved in 2011; and vortioxetine (Lu AA21004), in development] 
inhibit 5-HT reuptake and show partial agonism at 5-HT1A receptors (Page et al., 2002; Mork et 
al., 2012). Another drug (VN-2222; Romero et al., 2003), similar to vilazodone, was not 
developed due to industrial problems.   
 
As well as improving the onset of action of SSRIs, 5-HT1A agents are known to exert their own, 
potentially therapeutic, actions. 5-HT1A ligands with partial agonist activity seem to possess 
antianxiety (Schreiber and De Vry, 1993), antidepressant (Robinson et al., 1990), 
antiaggressive (Sanchez and Hyttel, 1994, de Boer and Koolhaas, 2005), and perhaps 
anticraving (Naranjo and Bremner, 1993) and anticataleptic (Prinssen et al., 2002) properties. 
Further, transgenic mice with a reduced expression of presynaptic 5-HT1A receptors 
(Richardson-Jones et al., 2010) and wild-type mice with siRNA-mediated supression of 5-HT1A 
autoreceptors have been reported to display antidepressant-like behaviour (Bortolozzi et al., 
2012). 
 
It has been noted that prolonged antidepressant treatments result in a tonic activation of 5-HT1A 
receptors in the dorsal hippocampus (CA3 region) (Haddjeri et al., 1998) and that activation of 
5-HT1A receptors in the dentate gyrus increases hippocampal neurogenesis (Jacobs et al., 
2000). These observations, together with the antidepressant properties of 5-HT1A agonists in 
preclinical tests (see Cryan et al., 2005 for review), have led to the suggestion of 5-HT1A 
agonists as a new class of antidepressants (Blier and Ward, 2003). However, although some 
agents of this kind (e.g. buspirone, gepirone) show antidepressant efficacy in placebo-controlled 
trials, their efficacy appears to be lower than that of SSRIs, and these drugs have not 
succeeded in the antidepressant market. Two main reasons may account for the clinical failure 
of 5-HT1A agonists. Firstly, most agents of this kind (especially the azapirones) show preferential 
activation of presynaptic 5-HT1A receptors. This reduces 5-HT cell firing and terminal 5-HT 
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release. Second, with few exceptions, these agents tend to show a reduced efficacy at 
postsynaptic 5-HT1A receptors. Thus, acute treatment with 5-HT1A receptors replaces the 
endogenous transmitter (5-HT, with a 100% efficacy) from postsynaptic sites by the partial 
agonist, with a lower efficacy than 5-HT. This results in a paradoxical reduction of the tone at 
postsynaptic 5-HT1A receptors. Higher doses (as those used in experimental animals) likely 
result in a greater activation of postsynaptic 5-HT1A receptors, which may explain the positive 
results in animal tests. The importance of activating postsynaptic 5-HT1A receptors for full 
antidepressant efficacy has been highlighted by a recent study showing that addition of the 
selective 5-HT1A receptor antagonist DU125530 to fluoxetine treatment did not accelerate nor 
enhance the efficacy of fluoxetine in a randomised, placebo-controlled, double-blind clinical trial. 
DU125530 has equal potency and occupancy of pre- and postsynaptic 5-HT1A receptors 
(Rabiner et al., 2002), and it is suggested that the blockade of postsynaptic 5-HT1A receptors 
cancelled the benefits obtained by enhancing presynaptic serotonergic function (Scorza et al., 
2011). 
 
Unlike azapirones and other first-generation 5-HT1A agonists, recently developed agonists hold 
promise to overcome these problems. For example, F15599 shows eightfold selectivity for 
postsynaptic 5-HT1A receptors in hippocampus vs. raphe 5-HT1A autoreceptors (Llado-Pelfort et 
al., 2010). Consistent with this preferential activation of postsynaptic 5-HT1A receptors, this 
agent shows superiority vs. classical 5-HT1A agonists in cognitive tests (Depoortere et al., 2010).  
 
3.2. 5-HT1B receptors 
Like the 5-HT1A receptor, 5-HT1B receptors are located pre- and postsynaptically and negatively 
coupled to adenylate cyclase. Yet unlike 5-HT1A autoreceptors, which are located in 
somatodendritically on 5-HT neurons, 5-HT1B autoreceptors are located on serotonergic axons, 
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where they locally regulate 5-HT synthesis and release. Postsynaptic 5-HT1B receptors (or 
heteroreceptors) are predominantly located in motor control centres such as the basal ganglia, 
where they control synaptic transmission (Castro et al., 1998; Sari, 2004). Evidence implicating 
5-HT1B receptors in the pathophysiology of depression comes from a number of converging 
lines of research. Two common genetic polymorphisms of 5-HT1B receptors, G861C (Huang et 
al., 2003) and C129T (Ruf and Bhagwagar, 2009), have been implicated in MDD and affective 
disorders. 5-HT1B receptor antagonists administered alone or with antidepressants have been 
shown to be effective in preclinical models of depression (Tatarczynska et al., 2004). On the 
other hand, the activation of 5-HT1B heteroceptors induces antidepressant-like behaviour 
(Chenu et al., 2008). 
 
Recent interest has also focused on p11, an s100 EF-hand protein family protein that 
colocalizes with 5-HT1B and 5-HT4 receptors (Egeland et al., 2011). P11 plays a central role in 
the modulation of 5-HT1B receptor function and is dysregulated in preclinical models of 
depression and postmortem MDD samples (Svenningsson et al., 2006). As with the 5-HT1A 
receptors, acute SSRI administration activates terminal 5-HT1B receptors, thus reducing 5-HT 
synthesis and release. Likewise, chronic administration of SSRI also results in desensitisation of 
terminal 5-HT1B autoreceptors (Neumaier et al., 1996), suggesting that plasticity in both the 5-
HT1A– and 5-HT1B–mediated autoregulatory function may be important in the therapeutic profile 
of SSRI. As observed with 5-HT1A receptors, the administration of 5-HT1B receptor antagonists 
augments the neurochemical and behavioural effects of SSRIs (Gobert et al., 1997, 2000a; 
Rollema et al., 1996, Hervas et al., 2000). Interestingly, co-administration of the selective 5-HT1A 
antagonist WAY-100635 and the 5-HT1B receptor antagonist SB-224289 acts additively to 
potentiate the neurochemical actions of the SSRI, fluoxetine (Fig. 1). This has led to the 
suggestion that combining 5-HT1A and 5-HT1B receptor antagonism can elevate serotonin and 
therefore potentially be an effective strategy to treat depression.  
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3.3. Other 5-HT1 receptors 
Unlike the 5-HT1A and 5-HT1B receptors, the clinical significance of the other 5-HT1-like (5-HT1D, 5-
HT1E, 5-HT1F) receptors remain less clear – although there is limited preclinical evidence linking 
some of these receptors to depression and associated conditions. Studies show that patients 
with depression have impaired sensitivity of the postsynaptic 5-HT1D receptors (Whale et al., 
2001). Similarly, another postmortem study of antidepressant-free suicide victims with a 
confirmed history of depression found a significantly higher density of 5-HT1D receptors in the 
globus pallidus (Lowther et al., 1997). The 5-HT1E receptor is highly expressed in the human 
frontal cortex and hippocampus, and it has been suggested that this distribution implies that 5-
HT1E receptors might be linked to cognition and memory (Klein et al., 2011). 
 
3.4. 5-HT2A receptors 
5-HT2A receptors, like the other members of the 5-HT2 receptor family, are preferentially coupled 
to Gq/11 to increase inositol phosphates and cytosolic [Ca2+], They are widely distributed at 
varying densities throughout the brain, with the highest density in the neocortex (Burnet et al., 
1995). There is generally a close overlap between the distribution of 5-HT2A mRNA and 
immunoreactivity, suggesting a postsynaptic location (Lopez-Gimenez et al., 2001b). In the 
cortex, 5-HT2A receptors have been shown to be localised on GABAergic interneurons as well 
as glutamatergic projection neurons in human and rodent brain (Santana et al., 2004; de 
Almeida and Mengod, 2007)  
 
Numerous antidepressants and antipsychotic agents bind with relatively high affinity at 5-HT2A 
receptors. Although there is no direct correlation between their receptor affinities and clinically 
effective doses, cumulative evidence indicates that the 5-HT2A receptor plays a role in 
depression. Several clinical studies have shown that atypical antipsychotic drugs (Carvalho et 
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al., 2008) and the antidepressant mirtazapine with affinity for α2-adrenoceptors and 5-HT2A 
receptors (Carpenter et al., 1999) augment the clinical response to SSRIs in treatment-resistant 
patients (Shelton et al., 2001). One common feature of these agents is their ability to occupy 5-
HT2 receptors in the brain at clinical doses and more specifically to block 5-HT2A-mediated 
responses (Marek et al., 2003). Given the large co-expression of 5-HT1A and 5-HT2A receptors in 
the neocortex (Amargos-Bosch et al., 2004), blockade of 5-HT2A receptors might enhance the 5-
HT1A receptor–mediated neurotransmission in cortical and limbic areas, an effect likely linked to 
the antidepressant efficacy (Fig. 2). Interestingly, the ventral parts of the anterior cingulate 
contain a higher proportion of 5-HT1A than of 5-HT2A receptors in the rodent (Santana et al., 
2004) and human brains (Palomero-Gallagher et al., 2009), suggesting that SSRIs may 
preferentially inhibit neuronal activity in this region compared to more dorsal cingulate areas. 
This is an interesting observation, given the role of the subcallosal cingulate (mainly Broadman 
area 25) in the improvement of treatment-resistant depressive patients by deep brain stimulation 
(Mayberg et al., 2005; Kennedy et al., 2011; Puigdemonet et al., 2012). 
 
Also, chronic administration of 5-HT2A antagonists has been reported to result in a paradoxical 
down-regulation of 5-HT2A receptors (Gray and Roth, 2001), which is predicted to be of benefit 
in the treatment of depression. Further, preclinical studies indicate that 5-HT2A antagonists 
possess anxiolytic properties, and the 5-HT2A antagonist ritanserin has been shown to have an 
antianxiety effect in humans (Bressa et al., 1987).  
 
3.5. 5-HT2B receptors 
The 5-HT2B receptor is largely expressed in peripheral tissues and has a restricted distribution in 
mammalian brain (Kursar et al., 1994; Bonhaus et al., 1995; Duxon et al., 1997). Interestingly, 
the 5-HT2B receptor mRNA is found in the dorsal raphe nucleus, suggesting a potential 
autoreceptor role (Bonaventure et al., 2002). 5-HT2B receptors mediate the well-known 
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contraction of rat fundus induced by 5-HT and appear to be involved in heart development 
(Nebigil et al., 2000). However, despite the limited knowledge regarding 5-HT2B receptor 
function in CNS, a recent study indicates its involvement in SSRI-mediated actions, showing 
also antidepressant-like properties of selective 5-HT2B receptor agonists (Diaz et al. 2012). The 
same study reports on the presence of 5-HT2B receptors in dorsal raphe 5-HT neurons and their 
stimulatory role on 5-HT release.  However, given the role of 5-HT2B receptors in the peripheral 
actions of 5-HT, potential new antidepressants targeting 5-HT2B receptors may have important 
pulmonary and cardiovascular side effects. 
 
3.6. 5-HT2c receptors 
5-HT2C receptors are predominantly located in the choroids plexus, cerebral cortex, 
hippocampus, substantia nigra and cerebellum (Abramowski et al., 1995) and, like the 5-HT2A 
receptor, have been implicated in many processes, including mood, motor behaviour and 
appetite (Millan, 2005). Likewise, alterations in their functional status have been detected in 
anxiodepressive states (Niswender et al., 2001; Wood, 2003), and 5-HT2C sites are known to be 
involved in the actions of several classes of antidepressant drugs. 
 
Although 5-HT2C receptors usually have a somatodendritic location, they may also be located on 
axon terminals in certain areas such as the septum and interpeduncular nucleus (presence of 
binding sites without mRNA expression) (Lopez-Gimenez et al., 2001a). Of interest, the 
localisation of 5-HT2C receptors in relation to serotonergic and GABAergic neurons has been 
studied in the anterior raphe nuclei. Such studies have found that 5-HT2C receptors are 
preferentially located on GABAergic interneurons (and not on serotonergic neurons), thereby 
supporting the idea that excitation of GABAergic interneurons through these 5-HT2C receptors is 
important in the suppression of serotonergic cell firing in the dorsal raphe and surrounding areas 
(Serrats et al., 2005). Likewise, 5-HT2C receptor immunoreactivity has been reported in 
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GABAergic cells of the prefrontal cortex (Liu et al., 2007) and in dopamine and GABA neurons 
of the mesolimbic pathway (Bubar et al., 2011). 
 
An altered editing of the mRNA encoding 5-HT2C receptors has been reported in the prefrotnal 
cortex of depressed suicide victims (Gurevich et al., 2002), suggesting an abnormal function of 
the receptor protein. Desensitisation of 5-HT2C receptors is also reported following chronic SSRI 
treatment. Preclinical data show that 5-HT2C antagonism augments the neurochemical and 
behavioural effects of SSRIs. For example, preclinical studies have shown that selective and 
nonselective 5-HT2C antagonists, potentiate the neurochemical effects of SSRIs on hippocampal 
and cortical extracellular 5-HT levels (Cremers et al., 2007; Cremers et al., 2004) and produces 
marked augmentation of the antidepressant effects of SSRIs in behavioural models of 
depression (Cremers et al., 2004). Despite the robust neurochemical effects when these agents 
are combined, 5-HT2C receptor antagonism alone has no significant effects on extracellular 
serotonin (Cremers et al., 2004). In contrast, various 5-HT2C receptor agonists were active in the 
forced swim test, suggesting antidepressant efficacy (Cryan and Lucki, 2000).  
 
Additionally, 5-HT2C receptors are involved in the tonic modulation of dopaminergic activity 
(Gobert et al., 2000b; Invernizzi et al., 2007). The role of the meslimbic/mesocrotical DA 
systems in schizophrenia together with the high affinity of atypical antipsychoitc drugs  5-HT2C 
receptors has prompted the interest in this receptor (Meltzer et al., 2003). However, the 
modulation of the ascending dopaminergic activity may be also of interest in antidepressant 
drug development. Hence, 5-HT2C receptors have been reported to be involved in 
antidepressant-like effects in the forced swim test (Clenet et al., 2001). 
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3.7. 5-HT3 receptors 
The 5-HT3 receptor is unique among all monoamine receptors in that it directly gates an ion 
channel–inducing rapid depolarisation that, in turn, causes the release of neurotransmitters 
and/or peptides. It is found throughout the brain and CNS and is in relatively high concentrations 
in the spinal cord and brainstem (area postrema), where it regulates vomiting. A number of 5-
HT3 receptor antagonists have been developed as antiemetics to be used with cancer 
chemotherapy. An antidepressant drug (litoxetine) was developed in the 1990s, combining 
SERT inhibition and 5-HT3 antagonism to prevent SSRI-induced gastrointestinal side effects 
(Angel et al., 1993). 
 
Within the forebrain, 5-HT3 receptors have been found in the entorhinal, frontal and cingulate 
cortices, hippocampus, and amygdala (Thompson and Lummis, 2006). Immunohistochemical 
studies indicate that there is a differential cellular localisation of postsynaptic 5-HT3 receptors 
within different central regions, depending on the nature of the neurons containing 5-HT3 
receptors. For instance, 5-HT3 receptor immunoreactivity was most abundant in postsynaptic 
dendrite sites in the hippocampus, but was primarily associated with presynaptic nerve endings 
in amygdala (Miquel et al., 2002).  
 
Importantly, 5-HT3 receptors control dopamine and acetylcholine release. Likewise, they control 
the GABAergic system and this interplay with other neurotransmitter systems (see below) is 
suggested to be a primary mechanism of effect for 5-HT3 ligands. Thus, different types of 
GABAergic interneurons in forebrain express 5-HT3 receptors (Morales and Bloom, 1997; Puig 
et al., 2004). The physiological excitation of 5-HT neurons excites cortical (and possibly 
hippocampal) GABAergic neurons (Puig et al., 2004), an effect that likely results in the inhibition 
of neighbouring excitatory neurons via GABAA and GABAB receptors. Limited preclinical 
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evidence also suggests that the 5-HT3 receptor plays a role in a variety of 
psychological/psychiatric disorders; however, the use of 5-HT3 receptor antagonists has met 
with little success. Nevertheless, there is accumulating evidence of interaction of antidepressant 
dugs with 5-HT3 receptors. Thus, antidepressant drugs with different mechanism of action show 
affinity for 5-HT3 receptors (Lucchelli et al., 1995) and behave as functional antagonists 
(Eisensamer et al., 2003). Likewise, chronic fluoxetine treatment desensitises 5-HT3 receptors 
(Fan, 1994), and SERT knockout mice show enhanced 5-HT3 receptor density compared with 
wild-type mice (Mossner et al., 2004). More recently, it has been shown that 5-HT3 receptor 
blockade with ondansetron potentiates the increase in extracellular 5-HT produced by 
citalopram in rat forebrain (Mork et al., 2012) Unlike the augmenting properties of 5-HT1A and 5-
HT1B receptor antagonists, involving presynaptic interactions at somatodendritic and terminal 
levels, this observation likely involves long loops from prefrontal cortex to midbrain serotonergic 
neurons (Fig. 3). Several reports also suggest a relationship between 5-HT3 receptors and 
anxiolytic/antidepressant behaviour. For example, transgenic knockout mice with deletion of the 
5-HT3 receptor exhibit anxiolytic behaviour (Kelley et al., 2003), in agreement with the anxiolytic 
effects of 5-HT3 receptor antagonists (Barnes et al., 1992).  
 
The use of 5-HT3 receptor antagonists have also been employed for the alleviation of substance 
abuse, a common comorbidity with most psychiatric disorders, including MDD (Ostacher, 2007). 
In this respect, 5-HT3 receptor antagonists have been reported to be particularly effective at 
reducing ethanol and morphine self-administration (Costall et al., 1993, Engleman et al., 2008). 
It is also interesting to note that a variety of antipsychotic drugs are noncompetitive 5-HT3 
receptor antagonists, and it has been suggested that this functional antagonism may contribute 
to their antipsychotic efficacy (Rammes et al., 2004). In addition, 5-HT3 antagonists abolish the 
emotion-potentiated startle effect in humans (Harmer et al., 2006) and reverse helpless 
behaviour in rats (Martin et al., 1992). Likewise, 5-HT3 receptor agonism attenuates 
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antidepressant-like effects in the forced swim test in rats (Nakagawa et al., 1998) and a 5-HT3 
receptor antagonist reduced immobility in the forced swim test (Kos et al., 2006). In line with 
these observations, the 5-HT3 receptor antagonist ondansetron showed antidepressant-like 
properties in the tail suspension and forced swim tests, augmenting also the effects of fluoxetine 
(Kos et al., 2006). Interestingly, the novel antidepressant drug vortioxetine [currently in 
development ( Baldwin et al., 2011); Alvarez et al., 2012) ] shows nanomolar affinity for several 
5-HT receptors, including 5-HT3 receptors (Mork et al., 2012), the clinical relevance of which 
deserves further exploration.  
 
3.8. 5-HT4 receptors 
5-HT4 receptors are located predominantly in the putamen, caudate nucleus, hippocampus, 
nucleus accumbens, globus pallidus and substantia nigra; and to a lesser extent in the 
neocortex, raphe and pontine nuclei and some areas of the thalamus (Varnas et al., 2003). 
Positron emission tomography (PET) scan studies show a somewhat more restricted regional 
distribution in human brain, with a high 5-HT4 receptor density in the caudate-putamen and 
much lower densities in frontal cortex and hippocampus (Marner et al., 2010). These receptors 
appear to be involved in the expression of genes of synaptic plasticity (Vidal et al., 2011), a 
common action of antidepressant drugs (Pittenger and Duman, 2008). The 5-HT4 receptor 
interacts with p11, a protein required for antidepressant effects mediated by 5-HT1B and 5-HT4 
receptors (Warner-Schmidt et al., 2009). Moreover, 5-HT4 knockout mice show an exaggerated 
inhibitory response of 5-HT neurons to the SSRI citalopram (Conductier et al., 2006), 
suggesting that 5-HT4 receptors are involved in the maintenance of the firing activity of 5-HT 
neurons during SERT inhibition. Thus, as observed with 5-HT1A and 5-HT2A receptors (Celada et 
al., 2001; Martín-Ruiz et al., 2001a), 5-HT4 receptors in prefrontal cortex control the firing rate of 
midbrain serotonergic neurons via descending inputs (Lucas et al., 2005) (Fig. 3). Moreover, 5-
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HT4 receptors mediate the synaptic transmission between the dentate gyrus and CA3 through 
the mossy fibre pathway. Interestingly, fluoxetine had a normalising effect on this pathway via 5-
HT4 receptor activation (Kobayashi et al., 2008). 
 
Preclinical studies show that administration of the 5-HT4 agonists RS 67333 and prucalopride 
reduces immobility in the forced swim test, thereby displaying the potential of the 5-HT4 receptor 
as a target for new antidepressant treatments (Lucas et al., 2007). Moreover, these studies 
show that administration of these agonists modifies rat brain parameters considered to be key 
markers of antidepressant action – namely, desensitisation of 5-HT1A autoreceptors, increased 
tonus on hippocampal postsynaptic 5-HT1A receptors, and enhanced phosphorylation of the 
CREB protein and neurogenesis in the hippocampus. Importantly, these effects were already 
present after only 3 days’ treatment (Lucas et al., 2007), whereas they are usually observed 
only after 2- to 3-week treatments with SSRIs. It has been suggested that the more rapid 
response to 5-HT4 agonism is probably the result of parallel rapid and sustained activation of 5-
HT neuronal firing in the dorsal raphe nucleus (Duman, 2007). Increased 5-HT neuronal firing 
could also underlie the apparently greater efficacy of the 5-HT4 agonists relative to SSRIs, as 
the effect of reuptake inhibition is dependent on basal rates of 5-HT cell firing. Since the raphe 
nuclei do not appear to express 5-HT4 receptors, the ability of 5-HT4 receptors to stimulate 
serotonergic firing appears to involve activation of receptors located on neurons in the prefrontal 
cortex (Lucas et al., 2005). Although the identity of the cells that express 5-HT4 receptors and 
their connections with the serotonergic neurons of the dorsal raphe nucleus is not yet known, it 
is possible that they project to other regions that contribute to the antidepressant actions of 5-
HT4 agonists (Duman, 2007). 
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3.9. 5-HT6 receptors  
5-HT6 receptors are postsynaptic receptors with the highest expression in the striatum, nucleus 
accumbens, olfactory tubercle, and cortex, with moderate density in the amygdala, 
hippocampus, hypothalamus, thalamus and cerebellum (Branchek and Blackburn, 2000). There 
is considerable evidence for this receptor subtype playing a role in learning and memory (Rosse 
and Schaffhauser, 2010), as well as centrally regulated feeding behaviour (Heal et al., 2008).  
Hence, 5-HT6 receptors are considered new targets for cognitive enhancement (Mitchell et al., 
2006). Several tricyclic antidepressant drugs, such as amitriptyline, and atypical 
antidepressants, such as mianserin, display nanomolar affinity and antagonist activity at the 5-
HT6 receptor (Monsma et al., 1993). This finding, together with the distribution of the receptor in 
limbic and cortical brain areas, has led to the suggestion that 5-HT6 receptors play an important 
role in the pathogenesis and/or treatment of depression (Monsma et al., 1993). 
 
Preclinical studies have shown that 5-HT6 antagonists such as SB-399885 exert an 
antidepressant-like effect in the forced swim and tail suspension tests in rodents (rats and mice) 
(Wesolowska and Nikiforuk, 2007). Moreover, combining a subeffective dose of SB-399885 with 
ineffective doses of imipramine, desipramine, bupropion or moclobemide was shown to have an 
antidepressant effect in the forced swim test in rats (Wesolowska and Nikiforuk, 2008). This 
suggests that inhibition of the 5-HT6 receptor synergistically potentiates the effect of clinically 
used antidepressants, and it is interesting to speculate whether combining a lower dose of an 
antidepressant with a 5-HT6 receptor antagonist might accelerate the onset of action and 
minimize the side-effect profiles. Confusingly, other preclinical studies have indicated that 5-HT6 
agonists may also be useful in treating depression. For example, it has been suggested that 5-
HT6 receptor stimulation may be a mechanism initiating some of the biochemical and 
behavioural outcomes of antidepressants such as fluoxetine (Svenningsson et al., 2007). On the 
other hand, the 5-HT6 receptor agonist LY-586713 increased hippocampal BDNF expression – a 
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cellular marker of antidepressant action – after single administration (de Foubert et al., 2007) 
whereas SSRIs require repeated administration to elicit the same effect (Pittenger and Duman, 
2008). On the same line, the 5-HT6 receptor agonist EMD 386088 produced antidepressant-like 
and anxiolytic effects after intra-hippocampal administration (Nikiforuk et al., 2011). Thus, it is 
uncertain whether antagonists or agonists of this receptor will best treat depression. Moreover, 
the exact mechanism of action of 5-HT6 ligands to elicit antidepressant-like effects is unknown 
and may involve changes in other neurotransmitter systems (Dawson and Li, 2003; 
Wesolowska, 2007). 
 
3.10. 5-HT7 receptors  
The 5-HT7 receptor, as first cloned in 1993, is highly expressed in the thalamus, hypothalamus, 
hippocampus and cortex (Hedlund and Sutcliffe, 2004). Findings from immunolocalisation and 
autoradiography studies are generally consistent with the mRNA distribution pattern (Neumaier 
et al., 2001; Varnas et al., 2004), which suggests predominant somatodendritic localisation. 
Since its discovery, a physiological role for 5-HT7 receptors has been firmly established in the 
regulation of circadian rhythm, sleep, and mood (Hedlund, 2009).  
 
As with the 5-HT6 receptors, it was quickly noticed that several antidepressants (Monsma et al., 
1993, Mullins et al., 1999) and antipsychotics (Roth et al., 1994) have high affinity for the 5-HT7 
receptor, leading to much subsequent research in its antidepressant effects. One preclinical 
study in the rat showed that several antidepressants, both tricyclics and SSRIs, induce c-fos 
expression in a way consistent with 5-HT7 receptor activation within the suprachiasmatic 
nucleus, and that chronic antidepressant drug treatment leads to a down-regulation of 5-HT7 
receptor binding (Mullins et al., 1999). Preclinical studies also show an antidepressant-like and 
anxiolytic effect of the 5-HT7 receptor antagonist SB 269970 in rodents (Wesolowska et al., 
2006) as well as a synergistic interaction between subefficacious doses of this agent and 
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antidepressants, leading to reduced immobility in both the forced swim test and the tail 
suspension test (Bonaventure et al., 2007; Wesolowska et al., 2007). In addition, the genetic 
and pharmacological inactivation of 5-HT7 receptors partly reversed phencyclidine-induced 
deficits of pre-pulse inhibition, an animal model of antipsychotic activity (Semenova et al., 2008). 
In this respect, it should also be noted that the atypical antipsychotic aripiprazole, which has 
high affinity for the 5-HT7 receptor is sometimes used to augment the effect of traditional 
antidepressants (Berman et al., 2009). Similarly, a recent study has suggested that the 
antidepressant effects of amisulpride are due to its action at 5-HT7 receptors (Abbas et al., 
2009). Overall, the 5-HT7 receptor is now being considered a new promising target in 
antidepressant drug development (Stahl, 2010). 
 
4. Conclusions and implications for drug development 
Despite new advances in the antidepressant field implicating glutamatergic mechanisms (Zarate 
et al., 2006), it is likely that the development of new antidepressant drugs in upcoming years will 
still be based on the monoamine systems. In particular, the  serotonergic system is closely 
involved in the aetiology of depression and provides a rich opportunity for developing 
compounds with multiple and complementary modes of action. The literature review indicates 
that: 1) Presynaptic 5-HT1A and 5-HT1B autoreceptors play a major detrimental role in 
antidepressant treatments, whereas the stimulation of postsynaptic 5-HT1A receptors in 
corticolimbic networks is beneficial for the antidepressant action; 2) Blockade of 5-HT2A/2C 
receptors improves the actions of SSRIs, whereas 5-HT2B receptor activation enhances 
serotonergic activity and shows antidepressant-like activity in rodents (yet this observation 
requires further confirmation); 3) 5-HT3 receptor blockade can augment the antidepressant 
action of SERT inhibition; 4) 5-HT4 receptor activation appears to have antidepressant effects 
on its own and may augment SSRI effects; and 5) Blockade of 5-HT6 and 5-HT7 receptors may 
also improve the antidepressant effects of SERT inhibition. 
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Given the network, cellular and neurochemical complexity of the 5-HT system, its possible 
redundancies in terms of signalling pathways and the sometimes opposite role of some pre- and 
postsynaptic receptors (e.g. 5-HT1A), it seems clear that drugs acting on a single receptor are 
unlikely to overcome the limitations of SSRIs, although new molecular approaches with cellular 
specificity, such as siRNA strategies, may perhaps overcome the limitations of drugs, which 
often do not discriminate between the same receptors expressed in different cellular phenotypes 
or brain regions. Therefore, it is likely that future antidepressant drugs overcoming the 
limitations of SSRIs and SNRIs will be developed on the basis of SERT inhibition (and perhaps 
NET inhibition) plus additional pharmacological activities at pre- and/or postsynaptic receptors. 
On the one hand, these activities should prevent the several 5-HT cell-based and network-
based negative feedback mechanisms that limit presynaptic serotonergic activity. This may 
include the selective reduction of 5-HT1A and/or 5-HT1B autoreceptor function plus the blockade 
of some postsynaptic receptors present in GABAergic neurons (5-HT3 and perhaps others) 
involved in the local and distal inhibition of serotonergic activity. On the other hand, since 
postsynaptic receptors play different and often opposing roles in experimental tests of 
depression, new compounds should show different postsynaptic activities, being agonists at 
certain receptors, such as 5-HT1A (yet with the aforementioned problem of suppressing 
presynaptic 5-HT activity) and 5-HT4 receptors and antagonists at other excitatory 5-HT 
receptors (e.g. 5-HT2A/2C 5-HT6, 5-HT7). Indeed, drugs showing all these pharmacological 
activities are technically unfeasible and might present many side effects due to their large 
number of pharmacological activities. However, it should be noted that recently developed 
compounds such as vilazodone and vortioxetine (Lu AA21004) go along these lines, as they 
add a partial 5-HT1A agonist activity to SERT inhibition, mimicking the pharmacological actions 
of the SSRI + pindolol combination (vortioxetine shows additional activities at other 5-HT 
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receptors; see above). Future drugs may incorporate new activities in parallel with a better 
knowledge of the 5-HT system.  
 
The antidepressant properties of 5-HT–enhancing drugs and of agonists/antagonists of 5-HT 
receptors derive from their modulation of corticolimbic networks whose function is altered in 
major depression, thereby normalising neurotransmitter function (glutamate, GABA) in these 
circuits. This effect may also be evoked by other monoamines, such as NE and DA, whose 
transporters are targeted by other antidepressant drugs (acetylcholine may also participate by 
improving cognitive symptoms). 5-HT exerts a widespread and complex regulation of the 
function of monoaminergic neurotransmission (Fink and Gothert, 2007) which is often reciprocal 
(e.g. serotonergic activity is tonically dependent on an α1-adrenergic input). As an example, 
activation of 5-HT1A receptors increases the release of NE and DA in forebrain, an effect likely 
involving 5-HT1A receptors in cortical pyramidal neurons projecting to the brainstem 
(HajosKorcsok and Sharp, 1996; Díaz-Mataix et al., 2005). On the other hand, 5-HT3 receptor 
blockade stimulates acetylcholine release (Barnes et al., 1989). Thus, changes in serotonergic 
activity evoke a series of parallel changes of these other monoamines, which may also 
contribute to the clinical action of antidepressant drugs acting primarily on the 5-HT system.  
 
Novel molecular mechanisms have been identified in the last decade that affect 
neurotransmitter function. Hence, microRNA are related to the pathophysiology and treatment of 
several CNS diseases, including depression (Mouillet-Richard et al., 2012), being also involved 
in the regulation of serotonergic neurotransmission (Millan et al., 2011). In particular, microRNA-
16 has been shown to modulate SERT expression and to be modulated by chronic 
antidepressant treatments (Baudry et al., 2010) and mediates the enhancement of hippocampal 
neurogenesis by SSRI (Launay et al., 2011). Moreover, small interference RNA (siRNA) has 
been used to modulate the expression of serotonergic genes and to evoke antidepressant-like 
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effects in rodents. Hence, the reduction of the expression of SERT increased serotonergic 
function and reduced the immobility in the forced-swim test (Thakker et al., 2005). Likewise, the 
selective reduction of 5-HT1A autoreceptor expression by a modified siRNA selectively targeting 
raphe 5-HT neurons (Bortolozzi et al., 2012) or by the local application of unmodified siRNA into 
the dorsal raphe (Ferrés-Coy et al., 2012) enhanced serotonergic function and evoked strong 
antidepressant-like effects. Overall, the use of these molecular strategies may add to 
pharmacological approaches in the search for new antidepressant treatments overcoming the 
limitations of existing drugs. 
 
In conclusion, the 5-HT system offers a large number of possibilities to develop new 
antidepressant treatments, based on combinations of different pharmacological activities in 
addition to SERT inhibition. Yet, these activities need to be carefully selected to overcome self-
limiting mechanisms of serotonergic activity as well as a selective activation or blockade of 
relevant postsynaptic receptors. In addition to drugs, new therapeutic approaches based on 
molecular approaches achieving cellular specificity may be possible. 
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Box 1. Main characteristics of the serotonergic system in mammalian brain 
 
• Low number of neurons: 250.000  5-HT neurons in the human brain (out of a total of 
1011)  
• Extensive arborisation (>106 nerve terminals/mm3) 
• Innervation of the whole neuraxis 
• Control of activity by descending (prefrontal cortex, lateral habenula, hypothalamus, etc.) 
and ascending (locus coeruleus, spinal cord) inputs to the raphe nuclei 
• Slow and regular discharge (pacemaker neurons): strong homeostasis 
• Neuronal activity dependent on sleep-wake cycles (REM-off neurons) 
• Very sensitive to self-inhibition through activation of 5-HT1A autoreceptors 
• Rich neurochemistry: 14 different postsynaptic receptors 
• Implication in a large number of physiological functions  
• Mutual control with monoaminergic cell groups  
  58
Figure legends 
 
 
Fig. 1. Role of 5-HT1A/1B autoreceptors in the mechanism of action of antidepressant drugs. A)  
Serotonin-enhancing drugs, such as the selective serotonin reuptake inhibitors (SSRIs) and the 
serotonin and norepinephrine reuptake inhibitors (SNRIs), exert two opposite actions on the 
active (extracellular) fraction of 5-HT in forebrain. On the one hand, SERT inhibition in forebrain 
nerve terminals increases the extracellular 5-HT concentration in corticolimbic areas. On the 
other hand, the excess 5-HT evoked by inhibition of SERT (maximal density in the raphe nuclei 
due to the presence of a dense network of 5-HT fibres (see B) activates raphe 5-HT1A 
autoreceptors, thus reducing serotonergic cell firing and impulse-dependent 5-HT release by 
forebrain axons. An additional negative feedback mechanism is exerted by the activation of 5-
HT1B autoreceptors in serotonergic nerve terminals. 5-HT autoreceptor desensitisation after 
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repeated treatment reduces the efficacy of negative feedback mechanisms and allows the 
active 5-HT concentration to increase several-fold. B) Increase in extracellular concentration 
produced by the SSRI fluoxetine (FLX, 1, 3 and 10 mg/kg) in six different regions of the rat 
brain. Note the large effect of SERT blockade by fluoxetine in the dorsal and median raphe 
nuclei at all doses in parallel with a moderate (if any) effect in forebrain regions. The effect of 
low doses is particularly relevant for clinical effects in depressed patients (20 mg/day for an 
average weight of 70 kg, i.e. 0.3 mg/kg·day in humans). C) The combined administration of the 
selective antagonists of 5-HT1A and 5-HT1B receptors (WAY-100635, 0.3 mg/kg s.c. and 
SB224289, 4 mg/kg i.p., respectively) augmented the effect of the SSRI fluoxetine (10 mg/kg 
i.p.) on extracellular 5-HT concentration in rat prefrontal cortex, mimicking the effects of 
autoreceptor desensitisation. D) Similarly, the knockdown of 5-HTH1A autoreceptors induced by 
a conjugated siRNA directed towards 5-HT1A autoreceptors (C-1A-siRNA) augmented the effect 
of fluoxetine (20 mg/kg i.p.) on extracellular 5-HT in mouse prefrontal cortex up to the level seen 
in constitutive 5-HT1A knockout mice (1A-KO). Note the small effect of fluoxetine in two groups 
of control mice (pre-treated with vehicle and nonsense siRNA –C-ms-siRNA, respectively). 
Results are means ± SEM values of extracellular 5-HT in the various experimental groups. 
Redrawn from data in Hervás and Artigas (1998), Hervás et al. (2000), and Bortolozzi et al. 
(2012). Abbreviations: DR, dorsal raphe nucleus; DHPC, dorsal hippocampus; MnR, median 
raphe nucleus; PFC, prefrontal cortex; STR, dorsal striatum; VHPC, ventral hippocampus. Panel 
A redrawn from Artigas et al. (2001) with permission.  
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Fig. 2. Schematic representation of the putative antidepressant mechanism of 5-HT2A receptor 
blockade. A) Low magnification image from the prelimbic area of the medial prefrontal cortex 
(mPFC) showing the presence of cells expressing 5-HT1A (left panel) and 5-HT2A receptor 
mRNA (right panel) labeled by double in situ hybridization using nonradioactive (digoxygenin, 
left) and radioactive (33P, right) oligonucleotides. Note the abundance of cells expressing one or 
other receptor, particularly in layers II-V. B) High-resolution image from the same area showing 
individual cells expressing both receptor transcripts, as denoted by the simultaneous presence 
of background dark cellular profiles (5-HT1A, digoxygenin-labeled) and black silver grains (5-
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HT2A, 33P-labeled). C) Upper panel. The excess 5-HT produced by SERT inhibition in prefrontal 
cortex (PFC) activates excitatory 5-HT2A and inhibitory 5-HT1A receptors in pyramidal neurons 
projecting to other cortical as well as subcortical areas, including the limbic system. Lower 
panel. Due to the large coexpression of 5-HT2A and 5-HT1A receptors in PFC neurons (ca. 80%; 
Amargós-Bosch et al., 2004; see B), the blockade of 5-HT2A receptors enhances 5-HT1A 
receptor-mediated neurotransmission, thus changing the top-down control of PFC on 
corticolimbic networks. Panels A and B taken from Amargós-Bosch et al. (2004) with 
permission. 
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Fig. 3. Schematic representation of the functional connectivity between the medial prefrontal 
cortex (mPFC) and the dorsal and median raphe nuclei (DR(MnR), in relationship to the putative 
antidepressant mechanism of 5-HT3 receptor blockade. The activity of pyramidal neurons in 
PFC is controlled by a balance between excitatory inputs (AMPA, NMDA) from other cortical 
areas, the thalamus, the hippocampus and the amygdala, and inhibitory inputs (mainly GABAA, 
GABAB and mGluRII/III).  Monoamines may play both excitatory and inhibitory roles, depending 
on the receptor activated. 5-HT3 receptors are.expressed by GABAergic interneurons in the 
hippocampal formation (Morales and Bloom, 1997) and the medial prefrontal cortex (mPFC; 
Puig et al., 2004). 5-HT3 receptor-containing interneurons are located in upper cortical layers 
than those expressing 5-HT2A receptors, indicating that 5-HT3 receptors control excitatory inputs 
onto apical dendrites. 5-HT3 receptors are excited by the physiological release of 5-HT, this 
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enhancing the local inhibitory tone via GABAA and GABAB receptor activation. 5-HT3 receptor 
blockade may thus decrease local negative feedback on 5-HT release mediated by terminal 
GABAB heteroreceptors. Additionally, 5-HT3 receptor blockade may decrease the GABAA 
receptor-mediated tone on mPFC neurons projecting to midbrain, thus enhancing the activity of 
the ascending brainstem monoaminergic systems (serotonergic neurons of the DR/MnR; 
dopaminergic neurons of the ventral tegmental area, VTA; noradrenergic neurons of the locus 
coeruleus, LC) that are under the excitatory control of the PFC (Gabbott et al., 2005). Both 
mechanisms may account for the augmentation of SSRI effects by the selective 5-HT3 receptor 
antagonist ondansetron (Mork et al., 2012). Abbreviations: DR, dorsal raphe nucleus; LC, locus 
coeruleus; MnR, median raphe nucleus; VTA, ventral tegmental area. 
 
 
